FDA OKs Merck vaccine for 4 childhood diseases
Posted on: Tuesday, 6 September 2005, 12:54 CDT
NEW YORK (Reuters) - Merck & Co. Inc. on Tuesday said U.S. regulators have approved its combination vaccine to protect children 12 months to 12 years of age against measles, mumps, rubella and chickenpox.
The vaccine, called Proquad, which combines two established Merck vaccines, is the first approved in the United States to target all four diseases in a single shot, Merck said. It is also approved for use as a second dose of measles, mumps and rubella vaccine.
"The approval of Proquad makes it more likely that more children can gain protection against these four diseases because fewer shots can potentially mean better compliance," said Henry Shinefield, clinical professor of pediatrics and dermatology at the University of California School of Medicine at San Francisco and a Proquad clinical investigator.
Shares of Merck, which is currently battling a slew of product-liability lawsuits over its withdrawn painkiller Vioxx, were little-changed at $28.84 in early afternoon trading on the New York Stock Exchange.
Source: REUTERS
Related Articles
- ProQuad Vaccine Linked to Fever and Convulsions
- Merck Rotavirus Vaccine Not Causing Bowel Condition - CDC
- Merck's Gardasil Vaccine Not Proven Safe for Little Girls
- FDA Approves Merck's Shingles Vaccine
- FDA Approves ZOSTAVAX(R), Merck's New Vaccine for Prevention of Shingles in Adults Age 60 and Older
- Merck Says Shingles Vaccine Approved
- Merck Cancer Vaccine Faces Christian-right Scrutiny
- Merck Says Vaccine Could Prevent 350K Cases of Cervical Cancer
- Merck cancer vaccine prevents lesions
- Chinese Anti-Cancer Vaccine Approved for Clinical Research
 |
 |
User Comments (0)
RSS Feeds